Fragile X syndrome: An update on developing treatment modalities

ACS Chemical Neuroscience

Volumn 2, Issue 8, 2011, Pages 402-410

  Healy, Aileen ^a   Rush, Roger ^a   Ocain, Timothy ^a  

^a Seaside Therapeutics   (United States)

Author keywords

aminobutyric acid; fragile X mental retardation gene; fragile X mental retardation protein; Fragile X syndrome; metabotropic glutamate receptor 5

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4,5,6,7 TETRAHYDROISOXAZOLO[4,5 C]PYRIDIN 3 OL; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AFQ 056; AMPA RECEPTOR; ANILINOQUINAZOLINE DERIVATIVE; ARBACLOFEN; BENZAMIDE DERIVATIVE; CARBAMOYLOXIME DERIVATIVE; FENOBAM; FRAGILE X MENTAL RETARDATION PROTEIN; LITHIUM; MEMANTINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR 5 NEGATIVE ALLOSTERIC MODULATOR; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIME DERIVATIVE; OXYTOCIN; P21 ACTIVATED KINASE; RAC1 PROTEIN; RILUZOLE; RO 4917523; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; AUTISM; BIPOLAR DISORDER; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; FATIGUE; FRAGILE X SYNDROME; GABAERGIC TRANSMISSION; GENE MUTATION; HEADACHE; HUMAN; MENTAL DEFICIENCY; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; REVIEW; SEDATION; SIDE EFFECT;

Γ-AMINOBUTYRIC ACID; FRAGILE X MENTAL RETARDATION GENE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; METABOTROPIC GLUTAMATE RECEPTOR 5;

ALLOSTERIC REGULATION; ANIMALS; BACLOFEN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DISCOVERY; FRAGILE X SYNDROME; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; TREATMENT OUTCOME;

EID: 80051718820     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn200019z     Document Type: Review

References (104)

1. Martin, J. and Bell, J. (1943) A pedigree of mental defect showing sex-linkage J. Neurol. Neurosurg. Psychiatry 6, 154-157
2. Sutherland, G. R. (1977) Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium Science 197, 265-266 (Pubitemid 8130438)
3. Verkerk, A. J., Pieretti, M., Sutcliffe, J. S., Fu, Y. H., Kuhl, D. P., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., and Zhang, F. P. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome Cell 65, 905-914 (Pubitemid 121001321)
4. Crawford, D. C., Acuna, J. M., and Sherman, S. L. (2001) FMR1 and the fragile X syndrome: human genome epidemiology review Genet. Med. 3, 359-371
5. Symons, F. J., Byiers, B. J., Raspa, M., Bishop, E., and Bailey, D. B. (2010) Self-injurious behavior and fragile X syndrome: findings from the national fragile X survey Am. J. Intellect. Dev. Disability 115, 473-481
6. Chonchaiya, W., Schneider, A., and Hagerman, R. J. (2009) Fragile X: a family of disorders Adv Pediatr. 56, 165-186
7. Jacquemont, S., Hagerman, R. J., Leehey, M. A., Hall, D., Levine, R., Brunberg, J., Zhang, L., Jardini, T., Gane, L. W., Harris, S. W., Herman, K., Grigsby, J., Greco, C. M., Berry-Kravis, E., Tassone, F., and Hagerman, P. J. (2004) Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population JAMA, J. Am. Med. Assoc. 291, 460-469 (Pubitemid 38129750)
8. Bourgeois, J. A., Seritan, A. L., Casillas, E. M., Hessl, D, Schneider, A, Yang, Y, Kaur, I, Cogswell, J. B., Nguyen, D. V., and Hagerman, R. J. (2010) Lifetime prevalence of mood and anxiety disorders in fragile x premutation carriers J. Clin. Psychiatry 72, 175-182
9. Iwahashi, C. K., Yasui, D. H., An, H. J., Greco, C. M., Tassone, F., Nannen, K., Babineau, B., Lebrilla, C. B., Hagerman, R. J., and Hagerman, P. J. (2006) Protein composition of the intranuclear inclusions of FXTAS Brain 129, 256-271 (Pubitemid 43063776)
10. Greco, C. M., Berman, R. F., Martin, R. M., Tassone, F., Schwartz, P. H., Chang, A., Trapp, B. D., Iwahashi, C., Brunberg, J., Grigsby, J., Hessl, D., Becker, E. J., Papazian, J., Leehey, M. A., Hagerman, R. J., and Hagerman, P. (2006) Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS) Brain 129, 243-255 (Pubitemid 43063775)
11. Tassone, F., Hagerman, R. J., Taylor, A. K., Gane, L. W., Godfrey, T. E., and Hagerman, P. J. (2000) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome Am. J. Hum. Genet. 66, 6-15 (Pubitemid 30481464)
12. Jin, P., Zarnescu, D., Zhang, F., Pearson, C. E., Lucchesi, J. C., Moses, K., and Warren, S. T. (2003) RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila Neuron 39, 739-747 (Pubitemid 37088087)
13. Qin, M., Entezam, A., Usdin, K., Huang, T., Liu, Z. H., Hoffman, G. E., and Smith, C. B. (2011) A mouse model of the fragile X premutation: Effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis Neurobiol Dis 42, 85-98
14. Kim, M., Bellini, M., and Ceman, S. (2009) Fragile X mental retardation protein FMRP binds mRNAs in the nucleus Mol. Cell. Biol. 29, 214-228
15. Fridell, R. A., Benson, R. E., Hua, J., Bogerd, H. P., and Cullen, B. R. (1996) A nuclear role for the Fragile X mental retardation protein EMBO J 15, 5408-5414 (Pubitemid 26336222)
16. Eberhart, D. E., Malter, H. E., Feng, Y., and Warren, S. T. (1996) The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals Hum. Mol. Genet. 5, 1083-1091 (Pubitemid 26318545)
17. Darnell, J. C., Jensen, K. B., Jin, P., Brown, V., Warren, S. T., and Darnell, R. B. (2001) Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function Cell 107, 489-499 (Pubitemid 33152784)
18. Darnell, J. C., Fraser, C. E., Mostovetsky, O., Stefani, G., Jones, T. A., Eddy, S. R., and Darnell, R. B. (2005) Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes Genes Dev. 19, 903-918 (Pubitemid 40548059)
19. Stefani, G., Fraser, C. E., Darnell, J. C., and Darnell, R. B. (2004) Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells J. Neurosci. 24, 7272-7276 (Pubitemid 39100696)
20. Siomi, H., Siomi, M. C., Nussbaum, R. L., and Dreyfuss, G. (1993) The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein Cell 74, 291-298 (Pubitemid 23221705)
21. Laggerbauer, B., Ostareck, D., Keidel, E. M., Ostareck-Lederer, A., and Fischer, U. (2001) Evidence that fragile X mental retardation protein is a negative regulator of translation Hum. Mol. Genet. 10, 329-338 (Pubitemid 32166544)
22. Villacé, P., Marión, R. M., and Ortín, J. (2004) The composition of Staufen-containing RNA granules from human cells indicates their role in the regulated transport and translation of messenger RNAs Nucleic Acids Res. 32, 2411-2420 (Pubitemid 38854795)
23. Ohashi, S., Koike, K., Omori, A., Ichinose, S., Ohara, S., Kobayashi, S., Sato, T. A., and Anzai, K. (2002) Identification of mRNA/protein (mRNP) complexes containing Puralpha, mStaufen, fragile X protein, and myosin Va and their association with rough endoplasmic reticulum equipped with a kinesin motor J. Biol. Chem. 277, 37804-37810
24. De Diego Otero, Y., Severijnen, L. A., van Cappellen, G., Schrier, M., Oostra, B., and Willemsen, R. (2002) Transport of fragile X mental retardation protein via granules in neurites of PC12 cells Mol. Cell. Biol. 22, 8332-8341 (Pubitemid 35304064)
25. Davidovic, L., Jaglin, X. H., Lepagnol-Bestel, A. M., Tremblay, S., Simonneau, M., Bardoni, B., and Khandjian, E. W. (2007) The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules Hum. Mol. Genet. 16, 3047-3058 (Pubitemid 350131323)
26. Ishizuka, A., Siomi, M. C., and Siomi, H. (2002) A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins Genes Dev. 16, 2497-2508
27. Caudy, A. A., Myers, M., Hannon, G. J., and Hammond, S. M. (2002) Fragile X-related protein and VIG associate with the RNA interference machinery Genes Dev. 16, 2491-2496
28. Caudy, A. A. and Hannon, G. J. (2004) Induction and biochemical purification of RNA-induced silencing complex from Drosophila S2 cells Methods Mol. Biol. 265, 59-72
29. Plante, I., Davidovic, L., Ouellet, D. L., Gobeil, L. A., Tremblay, S., Khandjian, E. W., and Provost, P. (2006) Dicer-Derived MicroRNAs Are Utilized by the Fragile X Mental Retardation Protein for Assembly on Target RNAs J. Biomed. Biotechnol. 2006, 64347
30. Kaufmann, W. E. and Moser, H. W. (2000) Dendritic anomalies in disorders associated with mental retardation Cereb. Cortex 10, 981-991
31. Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., and Greenough, W. T. (1997) Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits Proc. Natl. Acad. Sci. U.S.A. 94, 5401-5404 (Pubitemid 27214795)
32. Huber, K. M., Roder, J. C., and Bear, M. F. (2001) Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1 J. Neurophysiol. 86, 321-325 (Pubitemid 32623237)
33. Dudek, S. and Bear, M. F. (1992) Homosynaptic long-term depression in area CA1 of hippocmpus and effects of N-methyl-D-aspartate receptor blockade Proc. Natl. Acad. Sci. U.S.A. 89, 4363-4367
34. Weiler, I. J. and Greenough, W. T. (1993) Metabotropic glutamate receptors trigger postsynaptic protein synthesis Proc. Natl. Acad. Sci. U.S.A. 90, 7168-7171 (Pubitemid 23222410)
35. Huber, K. M., Kayser, M. S., and Bear, M. F. (2000) Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression Science 288, 1254-1257
36. Weiler, I. J., Irwin, S. A., Klintsova, A. Y., Spencer, C. M., Brazelton, A. D., Miyashiro, K., Comery, T. A., Patel, B., Eberwine, J., and Greenough, W. T. (1997) Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation Proc. Natl. Acad. Sci. U.S.A. 94, 5395-5400 (Pubitemid 27214794)
37. Huber, K. M., Gallagher, S. M., Warren, S. T., and Bear, M. F. (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation Proc. Natl. Acad. Sci. U.S.A. 99, 7746-7750 (Pubitemid 34568762)
38. Bear, M. F., Huber, K. M., and Warren, S. T. (2004) The mGluR theory of fragile X mental retardation Trends Neurosci. 27, 370-377 (Pubitemid 38829251)
39. Dolen, G., Osterweil, E., Rao, B. S., Smith, G. B., Auerbach, B. D., Chattarji, S., and Bear, M. F. (2007) Correction of fragile X syndrome in mice Neuron 56, 955-962 (Pubitemid 350251119)
40. Gasparini, F., Lingenhohl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., Varney, M. A., Johnson, E. C., Hess, S. D., Rao, S. P., Sacaan, A. I., Santori, E. M., Velicelebi, G., and Kuhn, R. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38, 1493-1503 (Pubitemid 29457731)
41. Chuang, S. C., Zhao, W., Bauchwitz, R., Yan, Q., Bianchi, R., and Wong, R. K. (2005) Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model J. Neurosci. 25, 8048-8055 (Pubitemid 41254408)
42. Osterweil, E. K., Krueger, D. D., Reinhold, K., and Bear, M. F. (2010) Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome J. Neurosci. 30, 15616-15627
43. Aschrafi, A., Cunningham, B. A., Edelman, G. M., and Vanderklish, P. W. (2005) The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain Proc. Natl. Acad. Sci. U.S.A. 102, 2180-2185 (Pubitemid 40262032)
44. Yun, S. H. and Trommer, B. L. (2011) Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus J. Neurosci. Res. 89, 176-182
45. Krueger, D. D., Osterweil, E. K., Chen, S. P., Tye, L. D., and Bear, M. F. (2011) Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome Proc. Natl. Acad. Sci. U.S.A. 108, 2587-2592
46. Li, J., Pelletier, M. R., Perez Velazquez, J. L., and Carlen, P. L. (2002) Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency Mol. Cell. Neurosci. 19, 138-151 (Pubitemid 34211895)
47. Lauterborn, J. C. (2004) Stress induced changes in cortical and hypothalamic c-fos expression are altered in fragile X mutant mice Mol. Brain Res. 131, 101-109 (Pubitemid 39458283)
48. Nakamoto, M., Nalavadi, V., Epstein, M. P., Narayanan, U., Bassell, G. J., and Warren, S. T. (2007) Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors Proc. Natl. Acad. Sci. U.S.A. 104, 15537-15542 (Pubitemid 47502952)
49. Olmos-Serrano, J. L., Paluszkiewicz, S., Martin, B. S., Kaufmann, W. E., Corbin, J. G., and Huntsman, M. M. (2010) Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome J. Neurosci. 30, 9929-9938
50. Selby, L., Zhang, C., and Sun, Q.-Q. (2007) Major Defects in Neocortical GABAergic Inhibitory Circuits in Mice Lacking the Fragile X Mental Retardation Protein Neurosci. Lett. 412, 227-232 (Pubitemid 46109160)
51. Centonze, D., Rossi, S., Mercaldo, V., Napoli, I., Ciotti, M. T., De Chiara, V., Musella, A., Prosperetti, C., Calabresi, P., Bernardi, G., and Bagni, C. (2008) Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome Biol. Psychiatry 63, 963-973 (Pubitemid 351602272)
52. Chang, S., Bray, S. M., Li, Z., Zarnescu, D. C., He, C., Jin, P., and Warren, S. T. (2008) Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila Nat. Chem. Biol. 4, 256-263 (Pubitemid 351419125)
53. Pacey, L. K. K., Heximer, S. P., and Hampson, D. R. (2009) Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures Mol. Pharmacol. 76, 18-24
54. Takayanagi, Y., Yoshida, M., Bielsky, I. F., Ross, H. E., Kawamata, M., and Onaka, T. (2005) Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice Proc. Natl. Acad. Sci. U.S.A. 201, 16096-16101 (Pubitemid 41552873)
55. Sala, M., Braida, D., Lentini, D., Busnelli, M., Bulgheroni, E., Capurro, V., Finardi, A., Donzelli, A., Pattini, L., Rubino, T., Parolaro, D., Nishimori, K., Parenti, M., and Chini, B. Pharmacologic Rescue of Impaired Cognitive Flexibility, Social Deficits, Increased Aggression, and Seizure Susceptibility in Oxytocin Receptor Null Mice: A Neurobehavioral Model of Autism. Biol Psychiatry Feb 2011, not supplied.
56. Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., and Ethell, I. M. (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model J. Med. Genet. 46, 94-102
57. Klein, P. S. and Melton, D. A. (1996) A molecular mechanism fo the effect of lithium on development Proc. Natl. Acad. Sci. U.S.A. 93, 8455-8459 (Pubitemid 26269579)
58. Min, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., and Bauchwitz, R. P. (2009) Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential Neuropharmacology 56, 463-472
59. Yuskaitis, C. J., Mines, M. A., King, M. K., Sweatt, J. D., Miller, C. A., and Jope, R. S. (2010) Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome Biochem. Pharmacol. 79, 632-646
60. Liu, Z.-H., Chuang, D.-M., and Smith, C. B. (2010) Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome Int. J. Neuropsychopharmacol. 25, 1-13
61. Volk, L. J., Pfeiffer, B. E., Gibson, J. R., and Huber, K. M. (2007) Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation J. Neurosci. 27, 11624-11634 (Pubitemid 350006892)
62. Hayashi, M. L., Rao, B. S., Seo, J. S., Choi, H. S., Dolan, B. M., Choi, S. Y., Chattarji, S., and Tonegawa, S. (2007) Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice Proc. Natl. Acad. Sci. U.S.A. 104, 11489-11494 (Pubitemid 47175167)
63. Chen, L. Y., Rex, C. S., Babayan, A. H., Kramár, E. A., Lynch, G., Gall, C. M., and Lauterborn, J. (2010) Physiological activation of synaptic Rac > PAK (p-21 activated kinase) signaling is defective in a mouse model of fragile X syndrome J. Neurosci. 30, 10977-10984
64. Rodriguez, A. L. and R., W. (2007) Recent progress in the development of allosteric modulators of mGluR5 Curr. Opin. Drug Discovery Dev. 10, 715-722 (Pubitemid 350076392)
65. Jaeschke, G., Wettstein, J. G., Nordquist, R. E., and Spooren, W. (2008) mGlu5 receptor antagonists and their therapeutic potential Expert Opin. Ther. Pat. 18, 123-142 (Pubitemid 351377052)
66. Gasparini, F., Bilbe, G., Gomez-Mancilla, B., and Spooren, W. (2008) mGluR5 antagonists: discovery, characterization and drug development Curr. Opin. Drug Discovery Dev. 11, 655-665
67. Bach, P., Isaac, M., and Slassi, A. (2007) Metabotropic glutamate receptor 5 modulators and their potential therapeutic applications Expert Opin. Ther. Pat. 17, 371-384 (Pubitemid 46567157)
68. Lindsley, C. W. and Emmitte, K. A. (2009) Recent progress in the discovery and development of negative allosteric modulators of mGluR5 Curr. Opin. Drug Discovery Dev. 12, 446-457
69. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., and Hagerman, R. (2009) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome J. Med. Genet. 46, 266-271
70. Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., Neri, G., Chen, F., Hadjikhani, N., Martinet, D., Meyer, J., Beckmann, J. S., Delange, K., Brun, A., Bussy, G., Gasparini, F., Hilse, T., Floesser, A., Branson, J., Bilbe, G., Johns, D., and Gomez-Mancilla, B. (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056 Sci. Transl. Med. 3 (64) ra1-9
71. Kulkarni, S. S. and Newman, A. H. (2007) Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 17, 2074-2079 (Pubitemid 46394535)
72. Kulkarni, S. S. and Newman, A. H. (2007) Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 17, 2987-2991 (Pubitemid 46722599)
73. Zhang, P., Zou, M. F., Rodriguez, A. L., Conn, P. J., and Newman, A. H. (2010) Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5 Bioorg. Med. Chem. 18, 3026-3035
74. Felts, A. S., Lindsley, S. R., Lamb, J. P., Rodriguez, A. L., Menon, U. N., Jadhav, S., Jones, C. K., Conn, P. J., Lindsley, W., and Emmitte, K. A. (2010) 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats Bioorg. Med. Chem. Lett. 20, 4390-4394
75. Burdi, D. F., Hunt, R., Fan, L., Hu, T., Wang, J., Guo, Z., Huang, Z., Wu, C., Hardy, L., Detheux, M., Orsini, M. A., Quinton, M. S., Lew, R., and Spear, K. (2010) Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5 J. Med. Chem. 53, 7107-7118
76. Felts, A. S., Saleh, S. A., Le, U., Rodriguez, A. L., Weaver, C. D., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2009) Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5 Bioorg. Med. Chem. Lett. 19, 6623-6626
77. Zhou, Y., Rodriguez, A. L., Williams, R., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS Bioorg. Med. Chem. Lett. 19, 6502-6506
78. Wágner, G., Wéber, C., Nyéki, O., Nógrádi, K., Bielik, A., Molnár, L., Bobok, A., Horváth, A., Kiss, B., Kolok, S., Nagy, J., Kurkó, D., Gál, K., Greiner, I., Szombathelyi, Z., Keseru, G. M., and Domány, G. (2010) Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs Bioorg. Med. Chem. Lett. 20, 3737-3741
79. Galambos, J., Wágner, G., Nógrádi, K., Bielik, A., Molnár, L., Bobok, A., Horváth, A., Kiss, B., Kolok, S., Nagy, J., Kurkó, D., Bakk, M. L., Vastag, M., Sághy, K., Gyertyán, I., Gál, K., Greiner, I., Szombathelyi, Z., Keseru, G. M., and Domány, G. (2010) Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists Bioorg. Med. Chem. Lett. 20, 4371-4375
80. Spanka, C., Glatthar, R., Desrayaud, S., Fendt, M., Orain, D., Troxler, T., and Vranesic, I. (2010) Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity Bioorg. Med. Chem. Lett. 20, 184-188
81. Olpe, H. R., Demiéville, H., Baltzer, V., Bencze, W. L., Koella, W. P., Wolf, P., and Haas, H. L. (1978) The biological activity of d- and l-baclofen (Lioresal) Eur. J. Pharmacol. 52, 133-136 (Pubitemid 9214951)
82. Johnston, G. A., Hailstone, M. H., and Freeman, C. G. (1980) Baclofen: stereoselective inhibition of excitant amino acid release J. Pharm. Pharmacol. 32, 230-231 (Pubitemid 10111586)
83. Hill, D. R. and Bowery, N. G. (1981) 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain Nature 290, 149-152 (Pubitemid 11149692)
84. Henry, J. L. (1982) Effects of intravenously administered enantiomers of baclofen on functionally identified units in lumbar dorsal horn of the spinal cat Neuropharmacology 21, 1073-1083 (Pubitemid 13234609)
85. Haas, H. L., Greene, R. W., and Olpe, H. R. (1985) Stereoselectivity of L-baclofen in hippocampal slices of the rat Neurosci. Lett. 55, 1-4 (Pubitemid 15103497)
86. Fattore, L., Cossu, G., Martellotta, M. C., and Fratta, W. (2002) Baclofen antagonizes intravenous self-administration of nicotine in mice and rats Alcohol Alcohol. 37, 495-498
87. Bowery, N. G., Hill, D. R., Hudson, A. L., Doble, A., Middlemiss, D. N., Shaw, J., and Turnbull, M. (1980) (-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor Nature 283, 92-94 (Pubitemid 10170892)
88. Bowery, N. G., Doble, A., Hill, D. R., Hudson, A. L., Turnbull, M. J., and Warrington, R. (1981) Structure/activity studies at a baclofen-sensitive, bicuculline-insensitive GABA receptor Adv. Biochem. Psychopharmacol. 29, 333-341
89. Bowery, N. (1989) GABAB receptors and their significance in mammalian pharmacology Trends Pharmacol. Sci. 10, 401-407 (Pubitemid 19244476)
90. Sohn, J. W., Lee, D., Cho, H., Lim, W., Shin, H. S., Lee, S. H., and Ho, W. K. (2007) Receptor-specific inhibition of GABAB-activated K+ currents by muscarinic and metabotropic glutamate receptors in immature rat hippocampus J. Physiol. 580, 411-422 (Pubitemid 46577857)
91. Scanziani, M., Capogna, M., Gähwiler, B., and Thompson, S. M. (1992) Presynaptic inhibition of miniature excitatory synaptic currents by baclofen and adenosine in the hippocampus Neuron 9, 919-927
92. Isaacson, J. S. and Hille, B. (1997) GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons Neuron 18, 143-152 (Pubitemid 27053837)
93. Rogawski, M. A. and Wenk, G. L. (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease CNS Drug Rev. 9, 275-308 (Pubitemid 37254706)
94. Robinson, D. M. and Keating, G. M. (2006) Memantine: a review of its use in Alzheimer's disease Drugs 66, 1515-1534 (Pubitemid 44250755)
95. Erickson, C. A., Mullett, J. E., and McDougle, C. J. (2009) Open-Label Memantine in Fragile X Syndrome J. Autism Dev. Disord. 39, 1629-1635
96. Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., Oostra, B. A., and Seeburg, P. H. (2009) Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice J. Physiol. 587, 787-804
97. Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., Decle, P., Potanos, K., Cook, E., Salt, J., Maino, D., Weinburg, D., Lara, R., Jardini, T., Cogswell, J., Johnson, S. A., and Hagerman, R. (2006) Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial J. Child Adolesc. Psychopharmacol. 16, 525-540 (Pubitemid 44737208)
98. Erickson, C. A., Wend, N., Weiler, I. J., Greenough, W. T., Stigler, K. A., Wink, L. K., and McDougle, C. J. (2010) Open-label riluzole in fragile X syndrome Brain Res. 1380, 264-270
99. Ring, R. H., Schechter, L. E., Leonard, S. K., Dwyer, J. M., Platt, B. J., Graf, R., Grauer, S., Pulicicchio, C., Resnick, L., Rahman, Z., Sukoff Rizzo, S. J., Luo, B., Beyer, C. E., Logue, S. F., Marquis, K. L., Hughes, Z. A., and Rosenzweig-Lipson, S. (2010) Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist Neuropharmacology 58, 69-77
100. Lee, H. J., Macbeth, A. H., Pagani, J. H., and Young, W. S., 3rd. (2009) Oxytocin: the great facilitator of life Prog. Neurobiol. 88, 127-151
101. Bartz, J. A. and Hollander, E. (2008) Oxytocin and experimental therapeutics in autism spectrum disorders Prog. Brain Res. 170, 451-462 (Pubitemid 352010247)
102. Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., and Ethell, D. W. (2010) Open-label add-on treatment trial of minocycline in fragile X syndrome BMC Neurol. 10, 91
103. Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., and Greenough, W. T. (2008) Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome J. Dev. Behav. Pediatr. 29, 293-302
104. Kesler, S. R., Lightbody, A. A., and Reiss, A. L. (2009) Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study Am. J. Med. Genet., Part A 149A, 403-407